| Clinical Significance of the TK1-Specific Activity in the Early Detection of Ovarian Cancer. | Clinical Significance of the TK1-Specific Activity in the Early Detection of Ovarian Cancer.
Osredkar J, Jagarlamudi KK, Cviič D, Škof E, Cvjetićanin B, Zore A, Lukanović D, Eriksson S, Meglič L. | 01/26/2024 |
| TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells. | TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells.
Bitter EE, Skidmore J, Allen CI, Erickson RI, Morris RM, Mortimer T, Meade A, Brog R, Phares T, Townsend M, Pickett BE, O'Neill KL., Free PMC Article | 12/5/2023 |
| Transcription factor Dp-1 knockdown downregulates thymidine kinase 1 expression to protect against proliferation and epithelial-mesenchymal transition in cervical cancer. | Transcription factor Dp-1 knockdown downregulates thymidine kinase 1 expression to protect against proliferation and epithelial-mesenchymal transition in cervical cancer.
Wu M, Ye M. | 09/19/2023 |
| Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer. | Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer.
Tribukait B, Lundgren PO, Kjellman A, Norming U, Nyman CR, Jagarlmundi K, Gustafsson O., Free PMC Article | 03/30/2023 |
| Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. | Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.
Paoletti C, Barlow WE, Cobain EF, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM., Free PMC Article | 03/26/2022 |
| Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas. | Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas.
Jaamaa S, Nevala R, Jagarlamudi K, Tukiainen E, Blomqvist C, Sampo M. | 03/12/2022 |
| HSP90alpha combined with AFP and TK1 improved the diagnostic value for hepatocellular carcinoma. | HSP90α combined with AFP and TK1 improved the diagnostic value for hepatocellular carcinoma.
Tang Y, Li K, Cai Z, Xie Y, Tan X, Su C, Li J. | 09/18/2021 |
| AroCell TK 210 ELISA for determination of TK1 protein: age-related reference ranges and comparison with other TK1 assays. | AroCell TK 210 ELISA for determination of TK1 protein: age-related reference ranges and comparison with other TK1 assays.
Kumar JK, Holmgren S, Levedahl KH, Höglund M, Venge P, Eriksson S. | 09/4/2021 |
| Identification of a novel thymidylate kinase activity. | Identification of a novel thymidylate kinase activity.
Frisk JH, Eriksson S, Pejler G, Wang L. | 06/12/2021 |
| Serum AFU, GGT and TK1 levels in PHC patients and their correlation with clinicopathology and diagnostic value. | Serum AFU, GGT and TK1 levels in PHC patients and their correlation with clinicopathology and diagnostic value.
Gong G, Zheng K, Xue S, Hou J, Zhang Q. | 06/5/2021 |
| Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes. | Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
Wang Z, Zhang W, Huo B, Dong L, Zhang J., Free PMC Article | 04/3/2021 |
| Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. | Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors.
McCartney A, Malorni L., Free PMC Article | 02/20/2021 |
| Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. | Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.
McCartney A, Bonechi M, De Luca F, Biagioni C, Curigliano G, Moretti E, Minisini AM, Bergqvist M, Benelli M, Migliaccio I, Galardi F, Risi E, De Santo I, Romagnoli D, Biganzoli L, Di Leo A, Malorni L. | 02/6/2021 |
| Clinical Applicability of the Proliferation Marker Thymidine Kinase 1 in Head and Neck Cancer Patients. | Clinical Applicability of the Proliferation Marker Thymidine Kinase 1 in Head and Neck Cancer Patients.
Meirovitz A, Gross M, Leibovici V, Sheva K, Popovzer A, Barak V. | 02/6/2021 |
| Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer. | Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer.
Nisman B, Allweis TM, Carmon E, Kadouri L, Maly B, Maimon O, Meirovitz A, Peretz T. | 02/6/2021 |
| Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy. | Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Cabel L, Rosenblum D, Lerebours F, Brain E, Loirat D, Bergqvist M, Cottu P, Donnadieu A, Bethune A, Kiavue N, Rodrigues M, Pierga JY, Tanguy ML, Bidard FC., Free PMC Article | 01/16/2021 |
| Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level. | Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level.
Kataoka Y, Iimori M, Niimi S, Tsukihara H, Wakasa T, Saeki H, Oki E, Maehara Y, Kitao H., Free PMC Article | 10/24/2020 |
| upregulated in prostate cancer tissues | Identification of hub genes in prostate cancer using robust rank aggregation and weighted gene co-expression network analysis.
Song ZY, Chao F, Zhuo Z, Ma Z, Li W, Chen G., Free PMC Article | 07/25/2020 |
| Study demonstrates that, in plasma-derived exosomes, increase in TK1 and CDK9 mRNA copies is associated with clinical resistance of metastatic breast cancer to palbociclib. | Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M, Bertolini I, Crucitta S, Fontanelli L, Rofi E, De Angelis C, Diodati L, Cavallero D, Gianfilippo G, Salvadori B, Fogli S, Falcone A, Scatena C, Naccarato AG, Roncella M, Ghilli M, Morganti R, Fontana A, Danesi R. | 02/22/2020 |
| TK1 is significantly overexpressed in tumor samples from lung adenocarcinoma (LUAD) patients and this TK1 overexpression is associated with significantly reduced overall survival and cancer recurrence. Loss of TK1 in LUAD cells results in reduced Rho GTPase activity and reduced expression of GDF15. Ectopic expression of GDF15 can partially rescue TK1 knockdown induced LUAD growth and metastasis inhibition. | Loss of thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by reducing GDF15 expression.
Malvi P, Janostiak R, Nagarajan A, Cai G, Wajapeyee N., Free PMC Article | 02/15/2020 |
| TK1 elevated concentration in pleural effusion is a biomarker for prognosis in the malignant pleural effusion. | Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion.
Tian T, Li J, Hu W, Sun C, Zhou J., Free PMC Article | 01/11/2020 |
| Here, it is demonstrated that the human colorectal cancer cell line DLD1 with acquired resistance to trifluridine (FTD), a key component of the novel, orally administered nucleoside analogue-type chemotherapeutic drug trifluridine/tipiracil, lacks functional thymidine kinase 1 (TK1) expression because of one nonsense mutation in the coding exon | Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity.
Edahiro K, Iimori M, Kobunai T, Morikawa-Ichinose T, Miura D, Kataoka Y, Niimi S, Wakasa T, Saeki H, Oki E, Kitao H, Maehara Y. | 08/3/2019 |
| TK1 expression might have a supportive implication in assessing biological behavior and prognosis of lung cancer patients | TK1 overexpression is associated with the poor outcomes of lung cancer patients: a systematic review and meta-analysis.
Wei YT, Luo YZ, Feng ZQ, Huang QX, Mo AS, Mo SX. | 07/27/2019 |
| Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. | Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.
Jagarlamudi KK, Shaw M. | 07/27/2019 |
| These findings indicate that double immunostaining for TK1/CD31 can detect activated tumor vessels more accurately than staining for Ki67/CD31 and potentially could identify tumors that will respond to anti-angiogenic therapy. | Thymidine kinase-1/CD31 double immunostaining for identifying activated tumor vessels.
Okamura S, Osaki T, Nishimura K, Ohsaki H, Shintani M, Matsuoka H, Maeda K, Shiogama K, Itoh T, Kamoshida S. | 04/6/2019 |